Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction

European Journal of Clinical Investigation

Volumn 38, Issue 4, 2008, Pages 205-210

  Nijmeijer, R ^a,d   Meuwissen, M ^b   Krijnen, P A J ^a,d   Van Der Wal, A ^b   Piek, J J ^b   Visser, C A ^a,d   Hack, C E ^a,c,d   Niessen, H W M ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CRUCELL HOLLAND BV   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Acute myocardial infarction; Coronary arteries; Culprit lesions; sPLA 2 II

Indexed keywords

PHOSPHOLIPASE A2;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIRECTIONAL ATHERECTOMY; FEMALE; HEART INFARCTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MALE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; VASCULAR SMOOTH MUSCLE;

ACTINS; ADULT; AGED; ANGINA PECTORIS; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCYTES, SMOOTH MUSCLE; PHOSPHOLIPASES A2;

EID: 40749153977     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.01933.x     Document Type: Article

References (21)

1. Glaser KB, Mobilio D, Chang JY, Senko N. Phospholipase A2 enzymes: regulation and inhibition. Trends Pharmacol Sci 1993 14:92 8.
2. Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000 86:718 22.
3. Porela P, Pulkki K, Voipio-Pulkki LM, Pettersson K, Leppanen V, Nevalainen TJ. Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction. Basic Res Cardiol 2000 95:413 7.
4. Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002 251:338 47.
5. Jaross W, Eckey R, Menschikowski M. Biological effects of secretory phospholipase A (2) group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest 2002 32:383 93.
6. Campeau L. Letter: Grading of angina pectoris. Circulation 1976 54:522 3.
7. Braunwald E. Unstable angina. A classification. Circulation 1989 80:410 4.
8. Van der Loos CM, Das PK, Van den Oord JJ, Houthoff HJ. Multiple immunoenzyme staining techniques. Use of fluoresceinated, biotinylated and unlabelled monoclonal antibodies. J Immunol Meth 1989 117:45 52.
9. Schiering A, Menschikowski M, Mueller E, Jaross W. Analysis of secretory group II phospholipase A2 expression in human aortic tissue is dependent on the degree of atherosclerosis. Atherosclerosis 1999 144:73 8.
10. Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegard J, Claesson HE. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997 17:2257 63.
11. Hurt-Camejo E, Andersen S, Standal R, Rosengren B, Sartipy P, Stadberg E et al. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol 1997 17:300 9.
12. Romano M, Romano E, Bjorkerud S, Hurt-Camejo E. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler Thromb Vasc Biol 1998 18:519 25.
13. Anthonsen MW, Stengel D, Hourton D, Ninio E, Johansen B. Mildly oxidized LDL induces expression of group IIa secretory phospholipase A (2) in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2000 20:1276 82.
14. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E. Interferon-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J Biol Chem 2000 275:22895 904.
15. Nijmeijer R, Lagrand WK, Baidoshvili A, Lubbers YT, Hermens WT, Meijer CJ et al. Secretory type II phospholipase A (2) binds to ischaemic myocardium during myocardial infarction in humans. Cardiovasc Res 2002 53:138 46.
16. Bauriedel G, Hutter R, Welsch U, Bach R, Sievert H, Luderitz B. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc Res 1999 41:480 8.
17. Wilson HA, Allred DV, O'Neill K, Bell JD. Activities and interactions among phospholipases A2 during thapsigargin-induced S49 cell death. Apoptosis 2000 5:389 96.
18. Nijmeijer R, Willemsen M, Meijer CJ, Visser CA, Verheijen RH, Gottlieb RA et al. Type II secretory phospholipase A2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol 2003 285:H2218 H2224.
19. Meuwissen M, van der Wal AC, Niessen HW, Koch KT, de Winter RJ, Van der Loos CM et al. Colocalisation of intraplaque C reactive protein, complement, oxidised low-density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 2006 59:196 201.
20. Krijnen PA, Meischl C, Nijmeijer R, Visser CA, Hack CE, Niessen HW. Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction? Cardiovasc Hematol Disord Drug Targets 2006 6:113 23.
21. Spagnoli LG, Mauriello A, Sangiorgi G, Fratoni S, Bonanno E, Schwartz RS et al. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004 292:1845 52.